Dive into the archives.
- Biogen Reports 2 More Cases of PML with Tysabri
By THOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan PLC, the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since [...]
- 11th Case of PML Reported With Tysabri
The 11the patient on Tysabri has developed a potentially deadly brain infection.
This is what happened when three people who were on Tysabri and other medications for Multiple Sclerosis had previously contracted the brain infection and two died, according to InjuryBoard.com which tracks such drug reactions. Then, the drug was taken off the market briefly.
Biogen Idec, [...]
- Biogen Reports 13th Case of PML
By KEITH J. WINSTEIN
Biogen Idec Inc.’s disclosure of a debilitating brain infection in a patient taking its Tysabri multiple-sclerosis medicine sparked a selloff in shares of the biotechnology company Monday.
The disclosure, made Friday evening, marks the 13th case of the infection, called progressive multifocal leukoencephalopathy or PML, in a Tysabri patient. Three of the patients [...]
- 10th PML Case Confirmed by Biogen
Biogen Idec Inc. has reported a new case of a potentially lethal brain inflammation in a patient using its drug Tysabri, the tenth such case since the drug was reintroduced three years ago.
The company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives [...]
- Tysabri Side Effects Linked to 9th PML Infection Case
A new case of a rare, often lethal, brain infection has been linked to the multiple sclerosis drug Tysabri, making it the ninth case of progressive multifocal leukoencephalopathy (PML) infection potentially caused by side effects of Tysabri since the drug was put back on the market in July 2006.
Biogen Idec Inc., the maker of Tysabri, [...]
- Biogen Says Eighth Patient Has Infection From Tysabri
By Tom Randall
June 12 (Bloomberg) — Biogen Idec said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.
The patient was confirmed to have progressive multifocal leukoencephalopathy, or PML, on June 10, according to a report on Cambridge, Massachusetts-based Biogen’s Web site. [...]
- Biogen Idec announces sixth case of PML linked to use of Tysabri
Biogen Idec reported that another patient with multiple sclerosis taking Tysabri (natalizumab) was diagnosed with progressive multifocal leukoencephalopathy (PML) earlier this month, raising the total number of cases to six since July 2006. Biogen Idec’s shares were down as much as 4.3 percent.
The patient had been taking Tysabri for 31 months before developing the brain [...]
- MS Patients Aren’t The Only Ones Who Get PML Because of Drugs
UPDATE 2-Genentech withdraws Raptiva from U.S. market
LOS ANGELES, April 8 (Reuters) – Genentech Inc, which was acquired by Roche Holding AG last month, announced on Wednesday a phased voluntary withdrawal of psoriasis drug Raptiva from the U.S. market due to its link to a brain infection.
Raptiva has been associated with an increased risk of progressive [...]
- Biogen hopes to have PML-related test by year-end
By Toni Clarke
BOSTON (Reuters) – Biogen Idec Inc said on Wednesday it is developing a test that can identify the presence of a virus that can cause a potentially deadly brain infection in certain patients taking its multiple sclerosis drug Tysabri, and hopes to have it available by year-end.
Cecil Pickett, Biogen’s head of research and [...]
- Malaria Pill=The End of PML?
Elan shares soar on news of possible Tysabri side-effect treatment
SHARES IN drug company Elan bounced more than 10 per cent yesterday after news emerged of a possible treatment for a potentially fatal side effect of its multiple sclerosis therapy, Tysabri.
Biogen Idec, Elan’s partner in the development and sale of Tysabri, is testing the efficacy of [...]
